Kristen Webb
Family · Clinton, TNNPI 1982073680
Payments from drug & device makers
Across 330 payments — averaging $25.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Novo Nordisk$594
- Pfizer$553
- Lilly USA, LLC$484
- Amgen$375
- AstraZeneca$354
- plus $2K from 29 others
What the payments were for
- Speaking & faculty fees$3,01036%
- Travel & lodging$180%
- Food & beverage$5,22263%
- Education$751%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 55 | $3,772 |
| Novo Nordisk | 36 | $594 |
| Pfizer | 32 | $553 |
| Lilly USA, LLC | 44 | $484 |
| Amgen | 32 | $375 |
| AstraZeneca | 11 | $354 |
| Boehringer Ingelheim | 16 | $250 |
| Dexcom, Inc. | 8 | $174 |
| GSK | 10 | $171 |
| E.r. Squibb & Sons, L.L.C. | 8 | $138 |
| Astellas Pharma US Inc | 4 | $119 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $114 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $113 |
| Arbor Pharmaceuticals, Inc. | 7 | $110 |
| Phathom Pharmaceuticals, Inc. | 6 | $90 |
| Idorsia Pharmaceuticals US Inc | 5 | $90 |
| Amarin Pharma, Inc. | 5 | $83 |
| Axsome Therapeutics, Inc. | 4 | $74 |
| Merck | 4 | $68 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $64 |
| Otsuka America Pharmaceutical, Inc. | 3 | $63 |
| Abbott | 3 | $58 |
| Bayer | 3 | $50 |
| Sanofi-aventis U.S. LLC | 3 | $49 |
| Sunovion Pharmaceuticals Inc. | 3 | $46 |
| Philips North America LLC | 2 | $39 |
| Sumitomo Pharma America, Inc. | 2 | $38 |
| Azurity Pharmaceuticals, Inc. | 2 | $36 |
| Silk Road Medical, Inc. | 1 | $29 |
| Exact Sciences | 2 | $28 |
| Baxter Healthcare | 1 | $26 |
| Acera Surgical, Inc. | 1 | $23 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| Dynavax Technologies Corporation | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,325 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 39 | $34,698 |
| TrintellixVortioxetine Hydrobromide | 28 | $26,959 |
| MounjaroTirzepatide | 16 | $26,553 |
| JardianceEmpagliflozin | 19 | $18,275 |
| LinzessLinaclotide | 17 | $16,908 |
| VraylarCariprazine Hcl | 11 | $14,961 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 22 | $13,468 |
| JanuviaSitagliptin Phosphate | 17 | $13,018 |
| VascepaIcosapent Ethyl | 14 | $11,638 |
| Repatha SureclickEvolocumab | 14 | $8,529 |
| MyrbetriqMirabegron | 12 | $7,885 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $7,045 |
| Atrovent HfaIpratropium Bromide | 11 | $4,990 |
| SymbicortBudesonide/Formoterol Fumarate | 22 | $4,949 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 148 | $4,081 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $553 | $34,69839 claims |
| AbbVieLinzess, Vraylar, Synthroid | $3,772 | $33,26344 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $113 | $26,95928 claims |
| Lilly USA, LLCMounjaro | $484 | $26,55316 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $354 | $18,41744 claims |
| Boehringer IngelheimJardiance | $250 | $18,27519 claims |
| MerckJanuvia | $68 | $13,01817 claims |
| Astellas Pharma US IncMyrbetriq | $119 | $7,88512 claims |
| GSKAnoro Ellipta | $171 | $7,04511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,706 family providers in Tennessee.
Other family in Clinton
- Stacy BrownMt Juliet$719K
- Dana WebberKnoxville$499K
- Brandy BiedermanHixson$448K
- Cynthia MillerMurfreesboro$384K
- Tamera ThoenerNashville$254K
- April SwonerHermitage$246K
- Jennifer WilliamsNashville$213K
- Chantil JeffreysGermantown$195K
- Laura PorchCordova$148K
- Lori LankfordNashville$148K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.